Direct oral anticoagulants
220 results
181 - 220
Mitral regurgitation 
Bleeding risk scores lack accuracy in primary care settings (CACAO)
Interrupted versus uninterrupted anticoagulation for cardiac rhythm management device insertion- ACG guideline on managing acute lower gastrointestinal bleeding
- Transient ischaemic attack (TIA)
- Warfarin provides greater net benefit than rivaroxaban for patients with atrial fibrillation and rheumatic heart disease
- Edoxaban as effective as LMWH for treatment of cancer-associated VTE
- Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
- Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery
- Greater risk of serious bleeding with diltiazem vs metoprolol in adults with atrial fibrillation using apixaban or rivaroxaban
- Early DOAC initiation after acute ischemic stroke reduces recurrent strokes without increasing risk of intracranial bleeds (CATALYST)
- Home versus in‐patient treatment for deep vein thrombosis
- Assessment and treatment of a patient with bleeding diathesis
- Acute coronary syndrome
- Low molecular weight heparin for prevention of venous thromboembolism in patients with lower‐limb immobilization
- Dabigatran cost-effective for AF prophylaxis in some patients, not others
- Extended rivaroxaban prophylaxis following a medical inpatient stay does not provide a net benefit (MARINER)
- Apixaban is noninferior to dalteparin for venous thromboembolism associated with cancer
- Rivaroxaban similar to warfarin for patients with NVAF
- Deep vein thrombosis
- Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction): Cochrane systematic review
- Lumbar puncture
- For atrial fibrillation with stable coronary artery disease, edoxaban alone prevents more bad outcomes than edoxaban plus an antiplatelet agent
- A new bleeding risk score predicts major bleeding better than other scores in elderly patients who take DOACs
- Optimal treatment of acute venous thromboembolism
- Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents
- Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
- Angioplasty or stenting for deep venous thrombosis
- Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery in adults: Cochrane systematic review
- Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia
- Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism
- Fewer major bleeds with edoxaban than with warfarin, but treatment benefit unclear (ENGAGE-AF)
- Cerebral infarction (ischaemic stroke)
- Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage
- COVID-19 and other coronavirus infections
- Prevention of venous thromboembolism
- Antiplatelet therapy for prevention of death, myocardial infarction, and stroke